HomePharmacologyOther

Other

View Category

Other

Hypertensive Patients: Maximizing Doses or Adding New Drugs

Adding new medication in moderate doses to control hypertension conveniently maximizes efficacy, reduces adverse effects and minimizes...
solaci -
Learn More
Other

ESC 2021 | STEP: Blood Pressure Values in the Elderly, A Never-Ending Debate

The results of the STEP study were presented at the European Society of Cardiology (ESC) 2021 Congress!...
solaci -
Learn More
Other

ESC 2021 | GREENNESS: Surprising New Protective Factor against Cardiovascular Disease

What Is “Greenness”? This factor—which generally refers to the proximity to vegetation, as measured by satellite pictures—could...
solaci -
Learn More
Other

ESC 2021 | Empagliflozin in Heart Failure with Reduced and Preserved Ejection Fraction

The full results of the EMPEROR-Preserved study confirm as findings that empagliflozin decreases the risk of death...
solaci -
Learn More
Other

Polypharmacy in Older Adults Elderly: What Medication to Discontinue

Polypharmacy is certainly a problem in the elderly population. Forgetfulness, and drug and dose confusion can lead...
solaci -
Learn More
Other

ACC 2021 | Relive Renal Denervation with RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to...
solaci -
Learn More
Acute coronary syndromes

ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI

The combination sacubitril/valsartan following high-risk AMI did not reduce the risk of cardiac failure or cardiovascular risk in...
solaci -
Learn More
Acute coronary syndromes

Post MI Betablockers for Good?

Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long...
solaci -
Learn More